Development of a PET/SPECT agent for amyloid imaging in Alzheimer’s disease
In the search for a cure for Alzheimer’s disease (AD), efforts have been focused on preventing or reversing amyloid deposition in the brain. Efficacy evaluation of these antimyloid therapies would greatly benefit from development of a tool for the in vivo detection and quantitation of amyloid deposits in the brain. Toward this goal, we have developed a series of benzothiazole derivatives as amyloid-imaging agents for positron emission tomography (PET). To extend the potential of these amyloid-imaging agents for routine clinical studies, we also set out to develop iodinated benzothiazole derivatives that could be used as dual agents for either PET or the complementary single photon emission computed tomography (SPECT). Such dual agents would permit PET or SPECT studies using radiotracers with the same chemical identity but labeled with different radionuclides. This would facilitate the validation of clinical SPECT studies, based on quantitative PET studies. In this work we report the synthesis and biological evaluation of a potent, selective, and brain-permeable benzothiazole compound, 2-(3′-iodo-4′-methylaminophenyl)-6-hydroxy-benzothialzole, termed 6-OH-BTA-1-3′-I (4), which can be radiolabeled with either positron-emitting carbon-11 or single photon-emitting iodine-125/iodine-123. The synthesis and radiolabeling of [125I]4 or [11C]4 were achieved through direct iodination with sodium [125I]iodide in the presence of chloramine T or through radiomethylation with [11C]CH3I. In vitro amyloid binding assays indicated that [125I]4 bound to amyloid deposits in a saturable manner and exhibited affinities in the nanomolar concentration range. Binding studies of [125I]4 to postmortem human brain homogenates also showed preference of binding to frontal cortex in the AD homogenates relative to age-matched control homogenates or cerebellum from either AD or control. In vivo pharmacokinetic studies in normal mice following iv injection of [11C]4 indicated that the radioligand entered the brain readily at early time points and cleared from the brain rapidly at later time points with a 2- to 30-min ratio >3. These results suggest that the new radioiodinated benzothiazole ligand might be useful as a surrogate marker for the in vivo quantitation of mayloid deposition in human brain for use with either PET or SPECT.
Index EntriesAlzheimer’s disease Aβ peptides PET SPECT carbon-11 iodine-125
Asenbaum S. (2003) PET and SPECT investigations in Alzheimer’s disease. Radiology
, 521–530.CrossRefGoogle Scholar
Hansch C. and Leo A. (1979) Substituent Constants for Correlation Analysis in Chemistry and Biology
, John Wiley, New York, NY.Google Scholar
Herholz K., Schopphoff H., Schmidt M., Mielke R., Eschner W., et al. (2002) Direct comparison of spatially normalized PET and SPECT scans in Alzheimer’s disease. J. Nucl. Med.
, 21–26.PubMedGoogle Scholar
Klunk W. E., Engler H., Nordberg A., Wang Y., Blomqvist G., et al. (2004) Imaging brain amyloid in Alzheimer’s disease using the novel PET tracer, PIB. Ann. Neurol.
, 306–319.PubMedCrossRefGoogle Scholar
Klunk W. E., Wang Y. M., Hung G. F., Debnah M. L., Holt D. P., et al. (2001) Uncharged thioflavin-T derivative bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci.
, 1471–1484.PubMedCrossRefGoogle Scholar
Klunk W. E., Wang Y., Huang G. F., Debnath M. L., Holt D. P., et al. (2003) The binding of 2-(4′-methyl-aminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J. Neurosci.
, 2086–2092.PubMedGoogle Scholar
Kung M. P., Hou C., Zhuang Z. P., Zhang B., Skovronsky D., et al. (2002) IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res.
, 202–210.PubMedCrossRefGoogle Scholar
Kung M. P., Skovronsky D. M., Hou C., Zhuang Z. P., Gur T. L., et al. (2003) Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer’s patients. J. Mol. Neurosci.
, 15–24.PubMedCrossRefGoogle Scholar
Mathis C. A., Bacskai B. J., Kajdasz S. T., McLellan M. E., Frosch M. P., et al. (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg. Med. Chem. Lett.
, 295–298.PubMedCrossRefGoogle Scholar
Mathis C. A., Wang Y., and Klunk W. E. (2004) Imaging amyloid plaques and neurofibrillary tangles in the aging human brain. Curr. Pharm. Design
, 1469–1492.CrossRefGoogle Scholar
Mathis C. A., Wang Y., Holt D. P., Huang G. F., Debnath M. L., et al. (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem.
, 2740–2754.PubMedCrossRefGoogle Scholar
Styren S. D., Hamilton R. L., Styren G. C., and Klunk W. E. (2000) X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer’ disease pathology. J. Histochem. Cytochem.
, 1223–1232.PubMedGoogle Scholar
Wang Y., Klunk W. E., Huang G. F., Debnath M. L., Holt D. P., et al. (2002) Synthesis and evaluation of 2-(3′-iod-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer’s disease. J. Mol. Neurosci.
, 11–16.PubMedCrossRefGoogle Scholar
Wang Y., Mathis C. A., Huang G.- F., Debnah M. L., Holt D., et al. (2003) Effects of lipophilicity on the affinity and non-specific binding of iodinated benzothiazole derivatives. J. Mol. Neurosci.
, 255–260.PubMedCrossRefGoogle Scholar